Shares of UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $27.43.
Several brokerages have issued reports on URGN. Guggenheim lowered their price target on UroGen Pharma from $40.00 to $15.00 and set a "buy" rating for the company in a report on Friday, May 23rd. Scotiabank began coverage on UroGen Pharma in a report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price target for the company. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target for the company. HC Wainwright downgraded UroGen Pharma from a "buy" rating to a "neutral" rating in a report on Thursday, May 22nd. Finally, The Goldman Sachs Group lowered their price target on UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd.
Read Our Latest Stock Analysis on URGN
Institutional Trading of UroGen Pharma
Several hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC lifted its holdings in UroGen Pharma by 94.3% during the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock worth $566,000 after purchasing an additional 24,839 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in UroGen Pharma by 216.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock worth $48,227,000 after purchasing an additional 2,983,368 shares during the last quarter. Parkman Healthcare Partners LLC lifted its holdings in UroGen Pharma by 6.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company's stock worth $4,348,000 after purchasing an additional 23,292 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in UroGen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock worth $258,000 after acquiring an additional 1,653 shares during the period. Finally, AQR Capital Management LLC increased its stake in UroGen Pharma by 347.5% during the 1st quarter. AQR Capital Management LLC now owns 114,066 shares of the company's stock worth $1,262,000 after acquiring an additional 88,577 shares during the period. 91.29% of the stock is owned by institutional investors and hedge funds.
UroGen Pharma Trading Up 1.8%
Shares of URGN traded up $0.07 during trading hours on Friday, hitting $4.04. 2,896,054 shares of the stock traded hands, compared to its average volume of 704,016. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 1-year low of $3.42 and a 1-year high of $20.70. The firm has a market capitalization of $186.27 million, a PE ratio of -1.28 and a beta of 0.66. The business has a fifty day moving average of $9.25 and a 200-day moving average of $10.39.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to analysts' expectations of $22.71 million. Analysts expect that UroGen Pharma will post -3.12 EPS for the current year.
UroGen Pharma Company Profile
(
Get Free ReportUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Featured Stories
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
